{
  "docId": "019de076-883a-72e4-86fb-18270cd4f977",
  "docSlug": "5c729b46407684473082dcb9c39fe3fc",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 25,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/3",
  "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
  "deckJsonHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977.json",
  "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.775
      },
      "kind": "list",
      "text": "Management Team with Strong Track Record: 3 approved drugs in 4 indications in the US and EU and multiple strategic deals; Cash runway into 1H2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3184da51-4340-4e6d-8a31-1d624fdcc8db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.595
      },
      "kind": "list",
      "text": "NXP900: Phase 1a commenced 3Q2023; First potential indications: YES1/SRC-driven solid tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "405d53f9-7504-4581-bf43-2567abe5d812",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.235
      },
      "kind": "list",
      "text": "Our Approach to Precision Medicine: Select and acquire novel, rationally-designed drug candidates; Focus on drug development for serious conditions of unmet need in oncology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d090a16c-cb5f-46cf-8516-c8ebffd93f65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.415
      },
      "kind": "list",
      "text": "NXP800: Fast Track Designation for platinum-resistant, ARID1a-mutated ovarian carcinoma; Phase 1b study ongoing in collaboration with ENGOT/GOG; Orphan Drug Designation for the treatment of cholangiocarcinoma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ddf014fb-8e2f-4955-9e28-443c7d2662ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Nuvectis Pharma – Key Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af97fd01-c0c5-42fc-be95-1a6c0af96f91",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "4492f187-fe35-4937-8288-c54a0144ba90",
      "evidence": "Nuvectis Pharma – Key Highlights",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 3,
      "from": 1,
      "beatId": "e0273d33-87c2-4251-bc5f-c93ae2285c5d",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document starts with an overview of Nuvectis Pharma and its pipeline, highlighting the need for new cancer treatments.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ba297281-7a07-4fab-9f22-5891aac6c136",
      "evidence": "The document presents early-stage results and potential market opportunity, implying that not investing in the company may result in missed opportunities.",
      "position": 0,
      "objective": "What is the cost of not investing in Nuvectis Pharma's pipeline?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}